Boston Scientific Loses Share To J&J; Rebate Program Could Buoy Sales
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's share of the U.S. drug-eluting stent market fell four percentage points to 55% during the third quarter as the firm failed to stop Johnson & Johnson/Cordis from stealing market share
You may also be interested in...
Kyphon Takes On Vertebroplasty In Pursuit Of Higher Reimbursement
In an effort to stake out higher kyphoplasty reimbursement, Kyphon will begin enrollment by the fourth quarter for a head-to-head trial comparing the spinal treatments vertebroplasty and kyphoplasty
Kyphon Takes On Vertebroplasty In Pursuit Of Higher Reimbursement
In an effort to stake out higher kyphoplasty reimbursement, Kyphon will begin enrollment by the fourth quarter for a head-to-head trial comparing the spinal treatments vertebroplasty and kyphoplasty
J&J Says It Will Continue To Make Acquisitions; Med-Tech Biz Shines In Q4
Johnson & Johnson says it will continue to invest in acquisitions following yet another strong quarter of medical device sales that salvaged its stagnant pharmaceutical business